Michael Hayden, Board Member at AbCellera Biologics (NASDAQ:ABCL), reported a large insider buy on September 26, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Hayden purchased 20,000 shares of AbCellera Biologics. The total transaction amounted to $98,200.
AbCellera Biologics shares are trading up 0.96% at $4.75 at the time of this writing on Wednesday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important
Insider transactions shouldn't be used primarily to make an investing decision, however, ...